ANS stress, FM and RA activity linked at EULAR meeting in Stockholm.
We seek to improve the lives of patients with autoimmune disease. Through immuno-autonomics, we understand how stress drives these diseases to excess.
What We Do
Inmedix has discovered and is working with partners to commercialize a novel class of diagnostics, therapeutics and cloud-based analytic strategies.
Our approach uses next-gen diagnostics and cloud-based data analytics on autonomic nervous system (ANS) control of stress responses within the brain. In the setting of an autoimmune disease, ANS stress can significantly intensify an autoimmune disease. We call it Immuno-autonomics. We seek to understand and block this process to allow current autoimmune disease therapies to work much better.
HRV linked with FM severity and effective TNFi treatment of RA at BSR meeting in Edinburgh.
First successful RCT of dopamine agonists to treat FM at ACR meeting in San Antonio.
Inmedix founded as a patent holding company.
Sale of dopamine agonist – FM international Inmedix patents.
First predictive ECG biomarker (HRV) for TNFi therapy.
Inmedix converts from a patent holding to a diagnostic/therapeutic company.
Inmedix builds commercial team.
First successful pilot study to enhance TNFi with ANS optimization.
Inmedix meets with FDA.
Inmedix UK Ltd subsidiary established, converts to Inmedix Inc and flied first ANS Therapeutics patent.
Research prototype created for clinical studies
Expanded research in COVID and long COVID
Created executive team from diagnostic industry experts
Inmedix® CloudHRV™ commercial unit completed and FDA pre-submission meeting
Anticipated FDA clearance of Inmedix® CloudHRV™ and commercialization